InnFocus, Inc. has raised $33.9 million in Series C financing to further develop its InnFocus MicroShunt glaucoma drainage system to treat early, moderate, and late stage primary open angle glaucoma.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CORONADO, Calif. — In patients with primary open-angle ...

InnFocus is developing the MicroShunt implant to lower and sustain intraocular pressure (IOP) for the treatment of primary open-angle glaucoma (mild to severe stage disease). The MicroShunt has shown ...

InnFocus has nabbed a pair of strategic ophthalmic investors in its Series C financing for $32.8 million. The cash infusion will go to the final phase of clinical testing for the startup's MicroShunt, ...

Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration has granted authorization to InnFocus to begin a phase 1 trial of its ...

Japan’s Santen Pharmaceutical shelled out $225 million in cash to acquire InnFocus, the maker of the MicroShunt, which is designed to treat patients in the mild to severe stage of glaucoma. Under ...

Innfocus (Miami) reported raising $32.8 million in a Series C funding round. The firm is one of several competing companies Medical Device Daily has dubbed the MIGS-6, in the minimally invasive ...

Russ Trenary has been named president and chief executive of Miami-based InnFocus Inc., a medical device company that has developed a patented micro-shunt for treating glaucoma, the company said in a ...

InnFocus Inc., which makes a drainage device for patients with glaucoma, has closed its Series C funding round at $33.9 million, according to a news release. The company announced in September that it ...